Adherence to anti-estrogen therapy in seniors with breast cancer: How well are we doing?

Breast Journal

Volumn 20, Issue 6, 2014, Pages 632-638

  Trabulsi, Nora ^a,b,c   Riedel, Kristen ^b   Winslade, Nancy ^a   Gregoire, Jean Pierre ^d   Meterissian, Sarkis ^a   Abrahamovicz, Michal ^b   Tamblyn, Robyn ^b,d   Mayo, Nancy ^b,d,e   Meguerditchian, Ari ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d UNIVERSITÉ LAVAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

adherence; anti estrogen therapy; breast cancer; seniors

Indexed keywords

ANASTROZOLE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIESTROGEN; AROMATASE INHIBITOR; BENZODIAZEPINE DERIVATIVE; LETROZOLE; TAMOXIFEN;

AGED; AGING; ARTICLE; BREAST CANCER; BREAST SURGERY; CANADA; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; DRUG SUBSTITUTION; DRUG USE; FEMALE; GERIATRIC PATIENT; HOSPITALIZATION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICATION POSSESSION RATIO; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; POLYPHARMACY; RISK FACTOR; TREATMENT WITHDRAWAL; BREAST NEOPLASMS; LONGITUDINAL STUDY; MEDICATION COMPLIANCE; MULTIVARIATE ANALYSIS; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; QUEBEC; TAMOXIFEN;

EID: 84912113496     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12328     Document Type: Article

References (48)

1. Clarke M,. Meta-analyses of adjuvant therapies for women with early breast cancer: the EBCTCG overview. Ann Oncol [Meta-Analysis] 2006; 17 (Suppl 10): x59-62.
2. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet [Meta-Analysis Research Support, Non-U.S. Gov't] 2005; 365: 1687-717.
3. Crivellari D, Price K, Gelber RD, et al,. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 2003; 21: 4517-23.
4. Wildiers H, Kunkler I, Biganzoli L, et al,. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007; 8: 1101-15.
5. Rossi A, Colantuoni G, Maione P, et al,. Chemotherapy of breast cancer in the elderly. Curr Med Chem [Review] 2005; 12: 297-310.
6. Bray F, McCarron P, Parkin DM,. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res [Research Support, Non-U.S. Gov't Review] 2004; 6: 229-39.
7. Gennari R, Audisio RA,. Breast cancer in elderly women. Optimizing the treatment. Breast Cancer Res Treat [Review] 2008; 110: 199-209.
8. Livi L, Paiar F, Saieva C, et al,. Breast cancer in the elderly: treatment of 1500 patients. Breast J 2006; 12: 353-9.
9. Osterberg L, Blaschke T,. Adherence to medication. N Engl J Med 2005; 353: 487-97.
10. Haynes RB, McDonald HP, Garg AX,. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288: 2880-3.
11. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A,. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-62.
12. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA,. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol [Research Support, U.S. Gov't, P.H.S.] 2004; 22: 3309-15.
13. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM,. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 2007; 45: 431-9.
14. McDonnell PJ, Jacobs MR,. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36: 1331-6.
15. Rasmussen JN, Chong A, Alter DA,. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177-86.
16. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC,. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303-10.
17. Partridge AH, Wang PS, Winer EP, Avorn J,. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.] 2003; 21: 602-6.
18. Cramer JA, Roy A, Burrell A, et al,. Medication compliance and persistence: terminology and definitions. Value Health [Review] 2008; 11: 44-7.
19. Sikka R, Xia F, Aubert RE,. Estimating medication persistency using administrative claims data. Am J Manag Care [Review] 2005; 11: 449-57.
20. Philibert MD, Pampalon R, Hamel D, Thouez JP, Loiselle CG,. Material and social deprivation and health and social services utilisation in Quebec: a local-scale evaluation system. Soc Sci Med 2007; 64: 1651-64.
21. Tamblyn R, Berkson L, Dauphinee WD, et al,. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med [Research Support, Non-U.S. Gov't] 1997; 127: 429-38.
22. Desch CE, McNiff KK, Schneider EC, et al,. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol [Research Support, Non-U.S. Gov't] 2008; 26: 3631-7.
23. Romano PS, Roos LL, Jollis JG,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075-9; discussion 81-90.
24. Quan H, Sundararajan V, Halfon P, et al,. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care [Research Support, Non-U.S. Gov't] 2005; 43: 1130-9.
25. Webb C, Koch T,. Women's experiences of non-invasive breast cancer: literature review and study report. J Adv Nurs [Review] 1997; 25: 514-25.
26. Davey C, White V, Warne C, Kitchen P, Villanueva E, Erbas B,. Understanding a ductal carcinoma in situ diagnosis: patient views and surgeon descriptions. Eur J Cancer Care 2011; 20: 776-84.
27. De Morgan S, Redman S, D'Este C, Rogers K,. Knowledge, satisfaction with information, decisional conflict and psychological morbidity amongst women diagnosed with ductal carcinoma in situ (DCIS). Patient Educ Couns [Research Support, Non-U.S. Gov't] 2011; 84: 62-8.
28. De Morgan S, Redman S, White KJ, Cakir B, Boyages J,. "Well, have I got cancer or haven't I?" The psycho-social issues for women diagnosed with ductal carcinoma in situ. Health Expect 2002; 5: 310-8.
29. van Gestel YR, Voogd AC, Vingerhoets AJ, et al,. A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 2007; 43: 549-56.
30. Liu Y, Perez M, Aft RL, et al,. Accuracy of perceived risk of recurrence among patients with early-stage breast cancer. Cancer Epidemiol Biomarkers Prev [Research Support, N.I.H., Extramural] 2010; 19: 675-80.
31. Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP,. Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med [Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 2001; 10: 589-98.
32. Gehi A, Haas D, Pipkin S, Whooley MA,. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005; 165: 2508-13.
33. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S,. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag 2008; 4: 269-86.
34. Grenard JL, Munjas BA, Adams JL, et al,. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med 2011; 26: 1175-82.
35. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ,. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007; 109: 832-9.
36. Somerset W, Stout SC, Miller AH, Musselman D,. Breast cancer and depression. Oncology [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review] 2004; 18: 1021-34; discussion 35-6, 47-8.
37. Fann JR, Thomas-Rich AM, Katon WJ, et al,. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry [Review] 2008; 30: 112-26.
38. Bruce ML, McAvay GJ, Raue PJ, et al,. Major depression in elderly home health care patients. Am J Psychiatry [Research Support, U.S. Gov't, P.H.S.] 2002; 159: 1367-74.
39. Crystal S, Sambamoorthi U, Walkup JT, Akincigil A,. Diagnosis and treatment of depression in the elderly medicare population: predictors, disparities, and trends. J Am Geriatr Soc [Research Support, U.S. Gov't, P.H.S.] 2003; 51: 1718-28.
40. Winer EP, Hudis C, Burstein HJ, et al,. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-29.
41. Sedjo RL, Devine S,. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011; 125: 191-200.
42. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA,. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat [Research Support, N.I.H., Extramural] 2006; 99: 215-20.
43. Wong JD, Bajcar JM, Wong GG, et al,. Medication reconciliation at hospital discharge: evaluating discrepancies. Ann Pharmacother [Research Support, Non-U.S. Gov't] 2008; 42: 1373-9.
44. Maurice A, Howell A, Evans DG, O'Neil AC, Scobie S,. Predicting compliance in a breast cancer prevention trial. Breast J 2006; 12: 446-50.
45. Yuen J, Persson I, Bergkvist L, Hoover R, Schairer C, Adami HO,. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect. Cancer Causes Control [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1993; 4: 369-74.
46. Balkrishnan R,. Predictors of medication adherence in the elderly. Clin Ther [Review] 1998; 20: 764-71.
47. Tamblyn R, Lavoie G, Petrella L, Monette J,. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol [Research Support, Non-U.S. Gov't] 1995; 48: 999-1009.
48. Owusu C, Buist DS, Field TS, et al,. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2008; 26: 549-55.